Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (16 quarters reported)
$197M in Q4 2014 → $53M now. Hover for any quarter.
As reported for the quarter ended September 30, 2018. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Urogen Pharma Ltd. | 70.4% | Unchanged | 789,297 | $37.3M |
| Mersana Therapeutics, Inc. | 18.0% | Unchanged | 955,709 | $9.56M |
| ID Immune Design Corp. | 8.1% | Unchanged | 1,236,394 | $4.27M |
| Agile Therapeutics, Inc. | 3.5% | Unchanged | 5,062,363 | $1.86M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2018 · filed November 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Eagle Pharmaceuticals, Inc. | Exited | −6,777 | −$513K | — |
quarter ended June 30, 2018 · filed August 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Urogen Pharma Ltd. | Trimmed | −306,727 | −$15.3M | 60.4% |
quarter ended March 31, 2018 · filed May 15, 2018
No position changes this quarter.
quarter ended December 31, 2017 · filed February 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Urogen Pharma Ltd. | Trimmed | −353,721 | −$13.2M | 54.2% |
| ID Immune Design Corp. | Trimmed | −176,886 | −$690K | 6.4% |
quarter ended September 30, 2017 · filed November 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Eagle Pharmaceuticals, Inc. | Trimmed | −3,645,507 | −$217M | 0.4% |
| ID Immune Design Corp. | Trimmed | −549,440 | −$5.69M | 14.7% |
| Urogen Pharma Ltd. | Trimmed | −1,584 | −$49.9K | 45.8% |
quarter ended June 30, 2017 · filed August 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Urogen Pharma Ltd. | New | +1,451,329 | +$26.2M | 33.5% |
| Mersana Therapeutics, Inc. | New | +955,709 | +$13.4M | 17.1% |
quarter ended March 31, 2017 · filed May 15, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Eagle Pharmaceuticals, Inc. | Trimmed | −299,794 | −$24.9M | 91.1% |
quarter ended December 31, 2016 · filed February 14, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Eagle Pharmaceuticals, Inc. | Trimmed | −430,686 | −$34.2M | 88.8% |
| AP Anthera Pharmaceuticals Inc. | Exited | −1,900,000 | −$5.99M | — |
Loading...
